# Efficacy and Safety of Etoricoxib/Cyanocobalamin Versus Etoricoxib for Acute Low Back Pain

> **NCT06517823** · PHASE3 · COMPLETED · sponsor: **Laboratorios Silanes S.A. de C.V.** · enrollment: 190 (actual)

## Conditions studied

- Acute Low-back Pain

## Interventions

- **DRUG:** Etoricoxib + Cyanocobalamin fixed dose
- **DRUG:** Etoricoxib fixed dose

## Key facts

- **NCT ID:** NCT06517823
- **Lead sponsor:** Laboratorios Silanes S.A. de C.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-04-26
- **Primary completion:** 2024-10-04
- **Final completion:** 2024-10-11
- **Target enrollment:** 190 (ACTUAL)
- **Last updated:** 2024-11-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06517823

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06517823, "Efficacy and Safety of Etoricoxib/Cyanocobalamin Versus Etoricoxib for Acute Low Back Pain". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06517823. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*